Publicaciones en las que colabora con Alfonso Jesús Domínguez-Gil Hurlé (139)

2016

  1. Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39

2015

  1. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman

    Clinical drug investigation, Vol. 35, Núm. 1, pp. 61-66

2014

  1. Facility-based inspection training in a virtual 3D laboratory

    Accreditation and Quality Assurance, Vol. 19, Núm. 5, pp. 403-409

  2. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study

    Patient Preference and Adherence, Vol. 7, pp. 729-739

  2. Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43

2012

  1. Juega a ganar 2.0

    Hospital Universitario de Salamanca

2011

  1. Etiquetado de los medicamentos inyectables que se administran en anestesia

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 58, Núm. 6, pp. 375-383

  2. Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma

    Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263

  3. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  4. Terapia personalizada en la infección por el VIH: Aplicación de criterios farmacogenéticos

    Anales de la Real Academia de Medicina y Cirugía de Valladolid, Núm. 48, pp. 75-99

2010

  1. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 169-176

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

  2. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798

  3. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2008

  1. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy

    Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489

2007

  1. El Instituto para el Uso Seguro de los Medicamentos (ISMP-España)

    Farmaceutico Hospitales, pp. 18-25

  2. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients

    Intensive Care Medicine, Vol. 33, Núm. 2, pp. 279-285

2006

  1. Prevalencia y factores asociados a los acontecimientos adversos prevenibles por medicamentos que causan el ingreso hospitalario

    Farmacia Hospitalaria, Vol. 30, Núm. 3, pp. 161-170

  2. Preventable adverse drug events in hospitalized patients

    Medicina Clinica, Vol. 126, Núm. 3, pp. 81-87